Company: HSDTW
Filing Date: 2025-10-02
Form Type: PRE 14A
Source: 0001104659-25-096093
Chunk: 4

Company: Solana Co
Filing Date: 2025-10-02
Form: PRE 14A
Chunk 4
---
        | ​ | ​ | ​ | ​ |  41 | ​ | ​ |
| ​ | DOCUMENTS INCORPORATED BY REFERENCE                                   | ​ | ​ | ​ | ​ |  43 | ​ | ​ |
| ​ | ADDITIONAL MATTERS                                                    | ​ | ​ | ​ | ​ |  43 | ​ | ​ |
| ​ | APPENDIX A — AMENDMENT 1 TO 2022 EQUITY INCENTIVE PLAN                | ​ | ​ | ​ | ​ | A-1 | ​ | ​ |

i

TABLE OF CONTENTS HELIUS MEDICAL TECHNOLOGIES, INC.
PROXY STATEMENT 2025 SPECIAL MEETING OF STOCKHOLDERS
[ ], 2025 QUESTIONS AND ANSWERS ABOUT THE SPECIAL MEETING Who is soliciting my vote? The Board of Directors (the “ Board ”) of Helius Medical Technologies, Inc. (the “ Company ”, “ we ” or “ us ”) is soliciting your proxy, as a holder of our Class A common stock (the “ Common Stock ”), for use at the special meeting of stockholders to be held on [ ], 2025, at [ ]a.m. Eastern Time, virtually at www.virtualshareholdermeeting.com/[ ] and any adjournment or postponement of such meeting (the “ Special Meeting ”). The Notice of Special Meeting of Stockholders (the “ Notice ”), proxy statement and form of proxy card are expected to be first mailed to stockholders of record on or about [ ], 2025. What is the purpose of the Special Meeting? At the Special Meeting, you will be voting on: • Proposal 1: To elect one new director to our Board of Directors; • Proposal 2: To approve, in accordance with Nasdaq Listing Rule 5635(a), the issuance of shares of our common stock upon the exercise of the Strategic Advisor Warrants issued to Pantera Capital Management LP and Summer Wisdom Holdings Limited; • Proposal 3: To approve, in accordance with Nasdaq Listing Rule 5635(a), the issuance of shares of our common stock upon the exercise of the Cryptocurrency Pre-Funded Warrants and Cryptocurrency Stapled Warrants issued in connection with our acceptance of Solana (SOL) cryptocurrency as consideration in our private placement offering; • Proposal 4: To approve an amendment to our 2022 Equity Incentive Plan to increase the number of shares of common stock available for issuance there